ARAP1-AS2: A Potential Drug Target and Biomarker (G100506020)

Target Name: ARAP1-AS2

NCBI ID: G100506020

ARAP1-AS2

Other Name(s): ARAP1 antisense RNA 2

ARAP1-AS2: A Potential Drug Target and Biomarker

ARP1-AS2 is a protein that is expressed in various tissues, including the brain, heart, and lungs. It is a key regulator of the cytoskeleton and is involved in the assembly and disassembly of actin filaments. The loss of ARP1-AS2 has been linked to a number of diseases, including neurodegenerative disorders, cancer, and cardiomyopathy. As a result, targeting this protein has become a focus of research in the field of biotechnology.

The Druggable Target

One of the challenges in studying ARP1-AS2 is its complex structure. The protein is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The transmembrane domain is known to be involved in the regulation of the cytoskeleton and is a potential target for small molecules. The coiled-coil domain is responsible for the protein's stability and functions as a protein complex. The T-loop domain is involved in the regulation of actin filament dynamics.

In addition to its structural features, ARP1-AS2 has been shown to play a role in a number of cellular processes. It is involved in the regulation of cell division, differentiation, and migration. It has also been shown to play a role in the regulation of the cytoskeleton, including the organization of microtubules and the distribution of organelles.

The Biomarker

The lack of effective therapies for certain diseases has led to the search for new biomarkers that can be used to diagnose and treat these diseases. ARP1-AS2 has been identified as a potential biomarker for a number of diseases, including neurodegenerative disorders, cancer, and cardiomyopathy.

In neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, the loss of ARP1-AS2 has been linked to the progression of the disease. Studies have shown that the levels of ARP1-AS2 are reduced in the brains of individuals with these disorders, and that these changes are associated with the decline in cognitive function and other symptoms.

In cancer, ARP1-AS2 has been shown to be involved in the regulation of cell division and the maintenance of the cytoskeleton. This makes it a potential target for cancer therapies that aim to inhibit cell division or disrupt the cytoskeleton.

In cardiomyopathy, ARP1-AS2 has been shown to be involved in the regulation of the cytoskeleton and the organization of heart muscle cells. The loss of ARP1-AS2 has been linked to the development of cardiomyopathy, and studies have shown that these changes are associated with the decline in cardiac function in individuals with this condition.

The Drug Target

The potential drug target for ARP1-AS2 is the regulation of the cytoskeleton and the maintenance of the cell-cell and cell-tissue contacts. This is an attractive target because it is involved in the regulation of a critical process that is involved in the development and maintenance of many tissues and organs.

ARP1-AS2 can be targeted with small molecules that affect the regulation of the cytoskeleton. This can include inhibitors of the formation of actin filaments, which can disrupt the organization of the cytoskeleton, or agents that disrupt the stability of the protein itself.

The Role of Small Molecules

The regulation of the cytoskeleton is a complex process that is influenced by a number of factors, including the levels of various cytoskeleton components, the availability of mechanical forces, and the levels of signaling molecules.

In addition to its role in the regulation of the cytoskeleton, ARP1-AS2 is also involved in the regulation of a number of other cellular processes. This makes it

Protein Name: ARAP1 Antisense RNA 2

The "ARAP1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARAP1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets